Vanda Pharmaceuticals (VNDA)
Vanda Pharmaceuticals Revenues: 8.141M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
VNDA Revenues Rankings
| Overall | 11th percentile | 3925 of 4431 |
| Sector | 29th percentile | 333 of 471 in Healthcare |
| Industry | 44th percentile | 73 of 132 in Biotechnology |
VNDA Revenues Range, Past 5 Years
| Minimum | 7.246M | Sep 2010 |
| Maximum | 12.42M | Mar 2010 |
| Average | 8.347M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these VNDA related companies
VNDA News
Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
May 29, 7:00PM PR Newswire
May 29, 7:00PM PR Newswire
$VNDA forms bearish "Continuation Diamond" chart pattern. http://stks.co/3l2O
about 22 days ago by RecogniaEvents
about 22 days ago by RecogniaEvents
Listen to $VNDA Q1 2012 earnings call - live at 10:00 AM, ondemand after - http://stks.co/3icr
about 24 days ago by earningscast
about 24 days ago by earningscast
@HighRiskBuyer $ARNA $NVS $VNDA $ONXX $DNDN $KERX nothing earlier, Looks like he made up his own false rumors.
about 43 days ago by jackofalltrade
about 43 days ago by jackofalltrade
Vanda Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012
Apr 18, 7:00AM PR Newswire
Apr 18, 7:00AM PR Newswire
Vanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist from Eli Lilly and Company
Apr 16, 7:00AM Benzinga
Apr 16, 7:00AM Benzinga
Beware of sexy Sofia Vengara-like stocks: http://stks.co/3J44 $$ $VNDA $ED
about 51 days ago by covestor
about 51 days ago by covestor
$VNDA http://stks.co/36vi hated bioname, can be interesting if breaks above 5$ with volumes and conviction - #BIOTECHS
about 65 days ago by LTbioinvestor
about 65 days ago by LTbioinvestor
Listen to $VNDA Q4 2011 earnings call (EPS -0.35 vs est -0.19) - live at 10:00 AM, ondemand after - http://stks.co/2OXj
about 108 days ago by earningscast
about 108 days ago by earningscast
Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
Feb 14, 7:00AM PR Newswire
Feb 14, 7:00AM PR Newswire
Vanda Pharmaceuticals to Announce Fourth Quarter 2011 Financial Results on February 14, 2012
Jan 18, 7:00PM PR Newswire
Jan 18, 7:00PM PR Newswire
Vanda signs exclusive license agreement with Megapharm for Fanapt in Israel
Dec 13, 7:08AM theflyonthewall.com
Dec 13, 7:08AM theflyonthewall.com
$TSPT reminds me of $VNDA, and $TSPT should put up a strong fight with the FDA just like $VNDA did.
about 322 days ago by jeremyzhou
about 322 days ago by jeremyzhou
Thinking short equities? Take a look at $CFP $FIRE $VNDA all them faces strong resistances!! #trading
about 375 days ago by patonet
about 375 days ago by patonet
$vnda waking up a bit . next week looking for that 8.15 break to start next leg up
about 399 days ago by danshep55
about 399 days ago by danshep55
$vnda still holding 2/3 looking to see if it can take out those 8.15 highs from other day
about 399 days ago by danshep55
about 399 days ago by danshep55
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| VNDA | 4.16 | -0.09 | -2.12% | 119.98M |
| VMW | 91.35 | -1.66 | -1.78% | 39.40B |
| VMI | 110.68 | -3.82 | -3.34% | 3.038B |
| VMED | 21.83 | -0.20 | -0.91% | |
| VMC | 33.87 | -0.78 | -2.25% | 4.479B |
| URG | 0.88 | -0.01 | -1.12% | 107.64M |
| URBN | 27.09 | -0.88 | -3.15% | 4.048B |
| URA | 6.93 | -0.20 | -2.81% | |
| UQM | 1.12 | -0.01 | -0.88% | 41.28M |
| UPS | 73.91 | -1.03 | -1.37% | 71.85B |
